But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
Full data from the Poseidon study confirm the anti-CTLA-4 MAb’s activity; with three chemo combos established, however, will it be enough?
The “left field but logical” buy sees Sanofi gaining a graft-versus-host disease therapy to add to its transplant offering.
Drugs prompting the most divergent opinions on outlook include Pfizer and Vir’s Covid-19 offerings and Biogen’s Aduhelm.
In an unprecedented situation Biogen sought to restrict the use of Aduhelm weeks after the drug’s approval. And the FDA said yes.